secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001140361-26-019573
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma Q1 net loss $47.6M; KRESLADI gets FDA accelerated approval; PRV sold for $180M
--------------------------------------------------------------------------------

- Net loss of $47.6M ($0.42/sh) narrowed from $61.3M ($0.56/sh) YoY.
- Cash $144.4M + $180M PRV proceeds extend runway into Q2 2028.
- FDA granted accelerated approval for KRESLADI in severe LAD-I in March 2026.
- Monetized Rare Pediatric Disease PRV for $180M on April 28, 2026.
- Pivotal Phase 2 trial of RP-A501 for Danon disease dosing reinitiated; RP-A701 first dosing expected mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126019573/0001140361-26-019573-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126019573/ef20072739_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-019573

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer